Logo image
Se connecter
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
Article de revue   Avec comité de lecture

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program

Fanny Le Du, Matthieu Carton, Thomas Bachelot, Mahasti Saghatchian, Barbara Pistilli, Etienne Brain, Delphine Loirat, Laurence Vanlemmens, Thomas Vermeulin, George Emile, …
The oncologist (Dayton, Ohio), Vol.28(10), pp.e867-e876
01/10/2023
PMID: 37589218

Résumé

Breast Cancer
There is limited real-world information on the impact of adjuvant and neoadjuvant anti-HER2-targeted treatments on patterns of recurrence and outcomes of patients with HER2+ metastatic breast cancer. This article reports on how anti-HER2 targeted treatment in the early setting impacts overall and progression-free survival under first-line treatment of patients with metastatic HER2+ breast cancer.

Indicateurs

1 Consultations de la notice

Détails

Logo image